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 Gastrointestinal (GI) motility is a physiological factor that affects oral drug 
absorption by controlling a drug's residence time in the GI tract.  The development of an 
oral drug absorption model, the pulsatile emptying transit (PET) model, which takes into 
account variations in GI motility due to the migrating motor complex (MMC) is 
described.  The absorption rate outputted by the PET model can be used as an input for 
pharmacokinetic models to estimate drug plasma concentratio -time profiles.  The effect 
of variations in GI motility on the drug plasma concentration-time profiles of high 
permeability and high solubility (BCS Class I) drugs was simulated.  Simulations showed 
that increases in the maximum plasma concentration (Cmax) greater than 10% can occur 
when drugs that have an effective permeability greater than 0.04 cm/min and a high 
dissolution rate (85% of the dose dissolves within 15 minutes) are dosed during phase III 
of the MMC.  
 Many explanations have been given for the appearance of double peaks in oral 
ranitidine plasma concentration-time curves.  Using a discontinuous PET model with a 2-
 x 
compartment pharmacokinetic model, parameter sensitivity analysis was done on the 
following parameters: dosing time relative to the MMC, dissolution rate, effective 
permeability in the duodenum and ileum, and intravenous pharmacokinetic parameters 
(k12, k21, kout, Vd).  Simulations suggest that the variety of shapes for ranitidine plasma 
concentration-time profiles with double peaks is a result of differences in these parameter 
values between individuals.  In addition, simulations showed that the dosing time relative 
to the MMC coupled with discontinuous absorption sites along the small intestine can 
explain the absence and presence of double peaks in oral ranitidine plasma concentration-
time profiles.   
  Cocrystals are non-covalently bonded crystal complexes with two or more 
components.  The formation of cocrystals offers a mens to alter the dissolution rate of a 
solid without changing covalent bonds. Dissolution experim nts with CBZ:NCT 
cocrystal and CBZ(III) crystal in ethanol, 2-propanol and ethyl acetate were conducted 
and the relative dissolution rates were compared with estimated relative dissolution rates 
based on stoichiometric cocrystal solubility.  Statistically significant differences in 
relative dissolution rates were not observed in all three solvents.       
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Chapter I 
Introduction and Background 
 
 The simplicity of swallowing a tablet with a glass of water to treat a disease 
stands in stark contrast with the difficulty of developing an orally delivered 
pharmaceutical product.  To achieve a desired pharmacologic effect, therapeutic amounts 
of drug need to be absorbed by the gastrointestinal tract,enter the systemic circulation 
and reach the sites of action.  Many factors can affect how well orally delivered 
compounds are absorbed.  These factors fall into threecategories: physicochemical 
properties of the compound, formulation of the compound, an human gastrointestinal 
physiology (Yu, Lipka et al. 1996).  A crucial step during early d ug development is 
determining whether a new compound that shows promising in vitro pharmacologic 
activity can be absorbed adequately by the human body without actually dosing the 
compound in humans.  If it is determined that sufficient absorption can be achieved, 
another key step in the development of the compound is determining a safe and effective 
dosing regimen in humans.  Predictive oral absorption models can significantly aid 
compound selection and optimization decisions at important drug development stages by 
providing reasonable estimates of human oral drug absorption for newly synthesized 
compounds and by allowing pharmaceutical scientists to run simulations to quantitatively 
understand how changing specific parameters may affect the rate, extent and variability 
of human oral drug absorption
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 The migrating motor complex (MMC) is a rhythmically recurring cycle of 
contractile activity in the stomach and small intestine that occurs during the fasted state.  
One of the primary roles of the MMC is to clear remaining ingested material from the 
stomach and small intestine into the colon.  As a consequence, the MMC influences the 
rate of gastric emptying and the intestinal residence timof drugs taken orally, which can 
be important determinants of the rate and extent of drug absorption in the fasted state.  
Additionally, the MMC may be a major source of inter-subject and intra-subject 
variability in oral drug absorption due to variable gastric emptying times and transit times 
caused by MMC cycle length differences between and within people and random dosing 
of drug during different phases of the MMC.  For these reasons, the MMC is an important 
physiological process to include in fasted state oral absorption modeling.  Including the 
effects of the MMC into predictive oral absorption models can help quantify variability in 
oral drug absorption, which would be especially useful for estimating a dose and dosing 
regimen selection of a drug candidate to be tested in clinical trials and for developing 
criteria to evaluate the bioequivalence between two formulations of a drug.  
 Most drugs are given orally as a solid dosage form such as a tablet.  One of the 
fundamental processes for oral drug absorption is dissolution because a drug must be 
dissolved before it can be absorbed by the gastrointestinal tract.  An extremely slow 
dissolution rate may limit the absorption capability of a promising new compound such 
that a decision to stop its development is made.  The physicochemical properties of a 
drug and drug formulation are important factors for drug absorption.  Synthesizing 
different solid forms of the same drug such as forming salts, hydrates, or polymorphs is a 
strategy used to change the physicochemical properties of drugs and improve their 
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absorption.  The formation of cocrystals offers another way to improve the 
physicochemical properties of a drug by making a new solid form of the drug.  Cocrystals 
are noncovalently bonded multiple component crystal complexes. Improved dissolution 
rates of cocrystals compared to the single component drug crystal have been reported 
(Remenar, Morissette et al. 2003; Childs, Chyall et al. 2004; McNamara, Childs et al. 
2006).  However, the mechanisms for improved dissolution rates of cocrystals compared 
to the single component drug crystal have not been well studied.  A better understanding 
of cocrystal dissolution mechanisms may aid in the selction of cocrystal components to 
achieve a desired drug dissolution profile and thus improve oral drug absorption. 
 
Anatomy and Physiology of the Gastrointestinal Tract 
 The GI tract consists of the mouth, esophagus, stomach, small intestine 
(duodenum, jejunum, ileum), and large intestine (caecum, olon, and rectum).   The GI 
tract not only serves as a region in the body where dig stion of ingested food and 
absorption of necessary nutrients to maintain life occur, b t it also prevents potentially 
harmful xenobiotics from entering the systemic circulation by acting as a barrier.  
Furthermore, it excretes any unabsorbed GI contents from the body.  The diversity in 
structure and environment of the GI tract is a reflection of the many essential functions 
that this part of the body performs. The stomach serve as a temporary reservoir for 
ingested food and is not considered to be a major site of absorption for most drugs due to 
its small surface area.  The acidic environment of the s omach (pH ≈ 2) may inhibit the 
growth of microrganisms and can denature ingested proteins to expose peptide bonds.  At 
the terminal end of the stomach is the pyloric sphincter, a ring like opening that controls 
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the flow and size of gastric contents that enter into the small intestine from the stomach.  
When strong contractions take place in the stomach, contents small enough to pass 
through the pylorus can empty out of the stomach.  The remaining contents in the 
stomach are mixed with stomach secretions and reduced in size so that they can pass 
through the pylorus upon subsequent contractions. 
 The small intestine is the predominant site for absorption in the GI tract due to its 
large surface area.  The different regions that make up the small intestine are the 
duodenum, jejunum, and ileum (Figure 1-1).  Finger-like projections, known as villi and 
microvilli which are located on the walls of the small intestine greatly increase the small 
intestine surface area (Figure 1-2).   
 The duodenum connects to the stomach through the pylorus and i  approximately 
25-35 cm long.  Bile, digestive enzymes, and bicarbonate are sec ted into the duodenum 
through the Sphincter of Oddi.  Bicarbonate is released from the pancreas to help 
neutralize acidic contents that are emptied from the stomach and prevent ulceration from 
occurring in the duodenal wall.  Bile secreted from the liv r and gall bladder helps 
emulsify fats for absorption while digestive enzymes secret d from the pancreas help 
break down components of food such as peptides and triglycerides.   
 The jejunum is located between the duodenum and ileum.  This part of the small 
intestine is where most of the nutrients are absorbed.  It is approximately 100-200 cm 
long and has an approximate pH of 7.5. 
 The ileum makes up the distal part of the small intestin .  It is approximately 200-
400 cm long and has an approximate pH of 7.4.  Notably, the ileum is the main 
absorption site for both vitamin B12 and bile salts. 
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 The large intestine receives unabsorbed material from the small intestine and 
stores it before it is excreted.  During the time thatunabsorbed material stays in the large 
intestine most of the remaining water is absorbed to compact the material into feces.  It 
has been commonly thought that drug absorption in the colon is low due to a low surface 
area and tighter tight junctions compared to the small intestine.  However, studies that 
evaluated regional permeabilities in rats using an Ussing chamber technique, showed that 
some drugs may be absorbed well in the colon.  It was found that hydrophilic compounds 
had decreased permeabilities in the colon compared to thejejunum.  However, 
hydrophobic compounds had similar or increased permeabilities n the colon compared to 
the jejunum (Ungell, Nylander et al. 1998).  This study suggests tha  significant 
absorption of hydrophobic drugs can occur in the colon.  
 The digestive system is unique in that veins converge from the stomach, small 
intestine and large intestine to form the portal vein, which brings venous blood to the 
liver instead of the right atrium of the heart.  Thus s bstances that are absorbed from the 
GI tract and enter the portal vein must pass through the liver before entering the systemic 
circulation. 
The Migrating Motor Complex 
 The stomach and small intestine have recurring cycles of intense contractile 
activity that occur during the fasted state known as the migrating motor complex (MMC).  
In the fed state, the MMC is disrupted and takes approximately 3.5 hours to return 
(Vantrappen, Janssens et al. 1977), although times of 10 hrs for the MMC to return have 
been observed (Kerlin and Phillips 1982).  The MMC is commonly described as having 
three phases; however, a fourth phase is sometimes mentioned.  Phase I is a quiescent 
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phase.  Phase I is followed by Phase II, which is described as having infrequent and 
irregular contractions.  During late Phase II, there is a period of increasing contractile 
activity.  This period is followed by an abrupt onset of regular and intense contractile 
activity that is characteristic of  Phase III, which has been referred to as the housekeeper 
of the small intestine (Szurszewski 1969).  Phase IV, is described as a brief transition 
period between Phase III and Phase I (Code and Marlett 1975).   
 Phase III contractile activity typically originates from the antrum/duodenum in 
humans.  However, Phase III may start in the proximal jejunum.  In one study it was 
found that 52 of the 66 recorded MMCs started in either the duodenum or antrum and 14 
of the 66 started near the proximal jejunum (Vantrappen, Janssens et al. 1977).  Phase III 
migrates aborally along the small intestine and when it reaches the terminal ileum, 
another Phase III begins in the proximal intestine (Figure 1-3).  At any given time during 
the fasted state, Phase III occupies a definite length of t e small intestine.  The length of 
small intestine occupied by Phase III decreases as it migrates aborally.  In humans, Phase 
III was measured to occupy 35 cm in the duodenum and 25 cm in the jejunum 
(Fleckenstein 1978).  The mean propagation velocity of Phase III d creases as well as it 
migrates aborally.  Mean propagation velocities of Phase III in human duodenum, 
jejunum, proximal ileum and terminal ileum are approximately 12 cm/min, 6 cm/min, 4.7 
cm/min, 1.3 cm/min, and 0.9 cm/min, respectively (Fleckenstei  1978; Kerlin and 
Phillips 1982). 
 Similar to animals, the MMC appears with great regularity in man (Fleckenstein 
and Oigaard 1978); however values of MMC duration between and humans can vary 
widely.  In studies done in the proximal part of the intestin  of five human subjects, it 
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was found that the duration of MMCs ranged from 122 to 172 minutes (Fl ckenstein 
1978).  In subsequent studies done in the entire small intestine, measured MMC durations 
ranged from 40 to 180 minutes with 80% of the MMC durations betwe n 60 to 140 
minutes.  The mean MMC duration was 110 ± 14 min (Fleckenstein and Oigaard 1978).   
Other researchers measured a MMC duration that ranged from 67 to 218 minutes with a 
mean of 144 ± 46 min (Takamatsu, Welage et al. 2002).  In measurements taken from the 
duodenum, the duration of Phase III activity remains fairly constant in the range of 3 to 
11 minutes.  The durations of Phase I and Phase II are variable and inversely related 
(Fleckenstein 1978; Takamatsu, Welage et al. 2002).  Intraluminal contents and nerve 
activity have been found to influence Phase II activity.  Increases in intraluminal contents 
increase the duration of Phase II activity and cholinergic nerves enhance Phase II activity 
(Takamatsu, Welage et al. 2002).  
 It has been suggested that one of the major purposes of the MMC is to clear 
unabsorbed contents from the stomach and small intestine in o the large intestine in 
preparation for the next meal (Szurszewski 1969; Vantrappen, Janssens et al. 1977).  The 
movement of contents in the small intestine is mostly at ributable to Phase III.   In 
radiological observations in humans, when a small amount f barium was injected into a 
jejunal segment that was in Phase III, it was propelled a distance of 25 to 35 cm with an 
estimated speed of 2.5 cm/s.  When contrast agent was injected during phase I, it 
remained stationary.  When injected during Phase II, a back and forth segmentary 
phenomena was observed with no significant net progression of the barium.  
Occasionally two or three consecutive contractions that occurred during phase II would 
progress the barium longer distances (Vantrappen, Janssens et al. 1977).  The time to 
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clear contents from a specific region of the intestine is dependent on the time it takes 
Phase III to migrate to that region.  In studies in dogs and sheep, major differences in 
intestinal transit times were observed depending on what phase of the MMC a bolus of 
phenol red was injected.  When the bolus was injected before Phase III was present, 
relatively short transit times were observed.  The longest transit times occurred when 
phenol red was injected during Phase I, after Phase III had already passed (Bueno, 
Fioramonti et al. 1975) (Figure 1-4). 
 
Migrating Motor Complex Effects on Gastric Emptying 
 The emptying of stomach contents predominantly occurs in a pulsatile manner 
and is a well coordinated event between the stomach, pylorus, and duodenum.  The 
coordination is especially apparent during Phase III of the MMC.  When the antrum 
contracts during Phase III, the pyloric sphincter relaxes and the duodenal bulb briefly 
stops contractile activity to accept a bolus from the stomach.  Once a bolus is emptied 
from the stomach the pyloric sphincter contracts preventing further flow of contents into 
the duodenum and Phase III contractile activity resumes in the duodenum (Figure 1-5).   
 Physical properties of the gastric contents such as volume, caloric content, 
viscosity, density, and particle size can influence gastric emptying rates.  Major 
differences exist in the gastric emptying patterns of digestibl  solids and nonnutrient 
liquids.  The emptying pattern of digestible solids is typically characterized by a lag time 
followed by a zero order decline.  Nonnutrient liquids empty from the stomach more 
rapidly than solids and their emptying follows a first order process (Figure 1-6).    
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 In addition to the physical properties of the gastric contents, the gastric emptying 
rate is influenced by gastrointestinal motility in the fasted state.   In a study that 
investigated the human gastric emptying rate of 50 mL and 200 mL of water during 
different phases of the MMC, it was found that the gastric emptying of liquids can be 
greatly influenced by the different phases of the MMC (Oberle, Chen et al. 1990).  The 
mean gastric emptying rate for 50 mL of water increased with increasing contractile 
activity.  The gastric emptying half lives for 50 mL of water were 61 min, 17 min and 9 
min for Phase I, Phase II and Late Phase II/Phase III, respectively.  The gastric emptying 
lag time for 50 mL of water also depended on the phases of the MMC and decreased with 
increasing contractile activity.  The gastric emptying lag times for 50 mL of water were 
19 min, 7.6 min, and 4 min for Phase I, Phase II and Late Phase II/Phase III, respectively.  
The gastric emptying of 200 mL of water was influenced differently by the phases of the 
MMC than 50 mL of water.  During Phase I and Phase II the gastric emptying rates were 
found not to be statistically different from each other.  The gastric emptying half lives for 
200 mL of water were 14 min, 10 min, and 5 min for Phase I, Phase II and Late Phase 
II/Phase III, respectively.  The gastric emptying lag times for 200 mL of water were 7 
min, 4 min, and 2 min for Phase I, Phase II and Late Phase II/Phase III, respectively.  The 
results of the study suggest that the gastric emptying of small volumes of liquid are more 
sensitive to stomach motility changes than larger volumes of liquid.  However, both 50 
mL and 200 mL of liquid had significantly increased rates of gastric emptying during 
Late Phase II/Phase III activity. 
 The MMC patterns in the stomach and duodenum are closely related.  In a study 
that observed 109 MMC cycles in the stomach and duodenum of five dogs, it was 
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observed that in all cases that the same recurrent cyclic pattern of action potential activity 
was seen in both the antrum and duodenum (Code and Marlett 1975).  Furthermore, the 
Phase III activity in the antrum and duodenum ended simultaneously for 14% of the 
cycles and within 3 minutes of each other for the remainder, which demonstrated a near 
simultaneous relationship in the MMC patterns between th  antrum and duodenum.  
 
Carbamazepine 
 Carbamazepine (Tegretol, dibenz [b,f] azepine-5-carboxamide) (Figure 1-7(a)) is 
a drug indicated for the treatment of epilepsy and trigeminal neuralgia.  It has a molecular 
weight of 236.28.  Four anhydrous polymorphs of carbamazepine have been identified.  
These include triclinic CBZ(I), trigonal CBZ(II), monoclinic CBZ(III) and a second 
anhydrous monoclinic form, CBZ(IV).  In aqueous environments, carbamazepine 
transforms from the anhydrous polymorphs to a dihydrated form, CBZ(D) (Kaneniwa, 
Ichikawa et al. 1987; Kobayashi, Ito et al. 2000; Murphy, Rodriguez-Cintron et al. 2002).  
The marketed form of carbamazepine is CBZ(III). 
 
Nicotinamide 
 Nicotinamide (3-pyridine carboxamide) (Figure 1-7(b)), is one of the water-
soluble vitamin B-complex vitamins.  More specifically, nicotinamide is the amide form 
of vitamin B3 also known as niacinamide.  It has a molecular weight of 122.12.  
Nicotinamide (NCT) is used to prevent and treat niacin deficiency and has low toxicity.  
 Nicotinamide has been used to solubililize many poor aqueous sol ble drugs.  The 
mechanism of solubility enhancement has been reported to be due to stacking 
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complexation between drug and nicotinamide and not cosolvency or micellar 
mechanisms (Sanghvi, Evans et al. 2007). 
 
Carbamazepine:Nicotinamide Cocrystal 
 A supramolecular design strategy was used to create 13 cocrystals with 
carbamazepine including carbamazepine:nicotinamide cocrystal (CBZ:NCT).  The 
formation of CBZ:NCT uses a homosynthon approach where  ca bamazepine dimers with 
the carboxamide moiety take advantage of additional electron donors and acceptors to 
interact with nicotinamide molecules (Fleischman, Kuduva et l. 2003).  As a result of 
the interactions, a hydrogen-bonded network forms (Figure 1-8).  
 
Research Objectives 
 The use of mathematical modeling methods to aid the developm nt of potential 
drugs has been increasing.  Mathematical models are especially beneficial for providing 
human estimates of oral absorption, pharmacokinetics, and pharmacodynamics for new 
drug candidates, since the drug candidates can not be dosed in humans without extensive 
animal experiments showing reasonable assurances of safety.  R alistic estimates of the 
rate and extent of human oral drug absorption by mathematical modeling methods require 
that the major factors affecting drug absorption by this route are accounted for.  
Therefore, the research objectives for this dissertation re: 
1.  To develop an oral absorption model that takes into acc unt pulsatile gastric emptying 
and the effects of the migrating motor complex on drug transit time through the small 
intestine and gastric emptying. 
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2.  To incorporate the absorption rate estimated by oral absorption model into a 
compartmental pharmacokinetic model to simulate plasma concentration-time profiles. 
3.  To simulate the effect of gastric emptying on the maxi um concentration (Cmax) of 
plasma concentration-time profiles for BCS Class I drugs. 
4.  To simulate oral drug absorption variability due to dosing at different phases of the 
migrating motor complex (MMC). 
5.  To simulate discontinuous absorption sites along the in est ne and dosing at different 
phases of the MMC to explain the absence and presence of double peaks in oral ranitidine 
plasma-concentration-time profiles. 
6.  To use mathematically constructed phase solubility dagrams to guide an investigation 
of the validity of using the stoichiometric solubility to estimate the relative dissolution 














































Figure 1-1  Diagram of small intestine (A.D.A.M. Medical Encyclopedia [Internet] 2007) 
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Development of the Pulsatile Emptying Transit (PET) Oral Absorption Model 
 
Introduction 
 Absorption is one of the processes that influence the pharmacokinetics of a drug.  
Other processes include distribution, metabolism, and excretion.  Pharmacokinetic 
models have traditionally used first order absorption assumptions to describe the oral 
absorption rate of drugs from the gastrointestinal tract.  However, oral drug absorption is 
a complex process affected by physicochemical properties of the drug, drug formulation, 
and gastrointestinal physiology factors.  The absorption rates of many drugs are not well 
described by a first order absorption rate (Zhou 2003).  Consequentially, erroneous 
predictions for dosage regimens may occur when first order oral absorption assumptions 
are made in pharmacokinetic modeling.  Developing absorption models that can more 
accurately represent the in vivo rate and extent of absorption from the gastrointestinal 
tract can improve dosage regimen predictions for orally delivered drugs. 
 The development of oral absorption modeling has evolved over the past half 
century and the models can generally be classified into three categories: quasi-
equilibrium, steady state, and dynamic models (Yu, Lipka et al. 1996).  The pH-partition 
hypothesis and absorption potential are examples of quasi-equilibrium models and are 
useful in forming drug absorption trends.  According to the pH-partition hypothesis, only 
unionized forms of compounds can be passively absorbed across lipid membrane so the 
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disassociation constant is an important characteristic that determines absorption across a 
membrane (Schanker, Tocco et al. 1958).  Although exceptions to the pH-partition 
hypothesis have been found, it is still a useful concept to consider when evaluating the 
absorption capability of a compound. 
 The absorption potential model built upon concepts of the pH-partition hypothesis 
to take into account the effects of solubility and dose on drug absorption (Dressman, 











where AP is the absorption potential, P is the partition coefficient, Fun is the fraction 
unionized at pH 6.5 and Do is a dimensionless number known as the dose number and is 








where D is the dose, Vo is the volume of water taken with the dose (250 mL) and Cs is the 
solubility of drug in the gastrointestinal tract fluid.  When several drugs that varied 
widely in their physicochemical properties were evaluated to test the ability of the 
absorption potential concept to predict fraction of absorbed, it was found that the 
absorption potential strongly correlated with fraction absorbed (Dressman, Amidon et al. 
1985). 
 While quasi-equilibrium models have been useful in qualitatively understanding 
drug absorption, quantitative absorption models that took into account gastrointestinal 
physiology needed to be developed to estimate the fraction of dose absorbed.  Two 
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approaches to estimate the fraction of drug absorbed include the steady state macroscopic 
mass balance approach and microscopic mass balance approach.  In the macroscopic 
mass balance approach, the small intestine is assumed to be a cylindrical tube where R is 
the radius and L is the length of the tube and a solution of drug flows through the 
intestine.  Applying mass balance principles, the difference in amount of drug that enters 
the intestine and leaves the intestine is equal to the amount of drug absorbed, which is 






     (2.3) 
where M is the amount of drug, Q is the volumetric flow rate, Co and Cout are the inlet 
and outlet concentrations, respectively.  Under the steady state assumption the fraction of 
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An is the dimensionless absorption number and represents the ratio between the intestinal 
residence time and effective absorption rate constant (Amidon, Lennernas et al. 1995): 
Q
πRLPeff
An =      (2.6) 
The macroscopic balance approach is useful for drugs that are already in solution form or 
have a high solubility.  However to include drug dissolution effects on absorption, the 
microscopic balance approach was developed.  The microscopic balance approach was 
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used to estimate the fraction of drug absorbed for suspensions of poorly soluble drugs 
(Oh, Curl et al. 1993).  Similar to the macroscopic balance approach, the microscopic 
balance approach assumes a steady state condition and the small intestine is assumed to 
be a cylindrical tube with radius = R and length = L.  A mass balance on the solid drug 
leads to the following equation which describes the change in particle radius with respect 
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From a mass balance on the solution phase, the following equation is derived to describe 
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where rp is the particle radius, ρ is the drug density, No/Vo is the particle number density, 
and D is the drug diffusion coefficient.  Dimensionless forms of the equations were 
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where, the dose number, Do, and absorption number, An, were previously defined in 
equations 2.2 and 2.6, respectively.  Dn is another dimensionless parameter known as the 
dissolution number and it is the ratio of the intestinal residence time to the dissolution 
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time of a particle with an initial radius of ro.  From mass balance of drug in the small 






a −−=      (2.12) 
where r*(1) and C*(1) are the dimensionless particle radius and dimensionless intestinal 
concentration at the end of the intestine.  A typical three-dimensional plot of the fraction 
of dose absorbed as a function of dose number and dissolution number that can be 
attained with the microscopic balance approach is shown in Figure 2-4.  The plot shows 
for a well absorbed compound (An = 1) at dose number and dissolution number close to 1 
the fraction of dose absorbed changes rapidly.  Since the macroscopic and microscopic 
balance approaches were derived with respect to intestinal position rather than time, the 
outputs of these models were not incorporated into time dependent pharmacokinetic 
models.  As a result, only an estimate of extent of absorption was outputted by these 
models. 
 Dispersion and compartmental models fall under the category of dynamic models 
because they output both the rate and extent of absorption.  A major advantage of 
dynamic models over previously discussed models is that absorption rates are simulated 
and can be inputted into traditional pharmacokinetic models to simulate plasma 
concentration-time profiles.  One of the first approaches used to simulate time dependent 
absorption processes was a dispersion model developed by Ni, Ho et al.  According to the 
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where C is the drug concentration, z is the axial distance from the stomach, Ka is the 
absorption rate constant, and α is the diffusion coefficient for longitudinal spreading (Ni, 
Ho et al. 1980).  Analytical solutions for simple cases of the dispersion model have been 
found, however the solutions are complex.   
 The development of compartmental models offers an alternative way to model 
dynamic oral absorption.  The compartmental modeling approach involves using one or 
more series of mixing tanks to represent the gastrointestinal tract.  A number of 
absorption models have been developed using the compartmental approach to simulate a 
wide range of pharmaceutical scenarios(Goodacre and Murray 1981; Dressman, Fleisher 
et al. 1984) (Dressman and Fleisher 1986; Oberle and Amidon 1987; Hintz and Johnson 
1989; Luner and Amidon 1993).  It was not until the compartmental and transit model 
(CAT) was developed that transit of drug through the intestine and the optimal number of 
compartments to describe that transit was considered in the development of 
compartmental oral absorption models.  To determine the number of mixing tanks that 
would best describe drug transit through the small intestine, data that measured 400 small 
intestine transit times was analyzed.  It was determined that seven mixing tanks best 
described the transit of contents through the small intestine (Yu and Amidon 1998).  The 
absorption rates estimated by the CAT model were incorporated into a pharmacokinetic 
model that predicted the plasma concentration-time profile of cefatrizine well (Figure 2-
5).  Numerous extensions to the CAT model have been made and the new model is 
currently called the advanced CAT (ACAT) model.  The ability of the ACAT program to 
simulate plasma concentration-time profiles of several drugs has been demonstrated 
(Agoram, Woltosz et al. 2001).  The commercial success of the ACAT model has 
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demonstrated the value of oral absorption modeling to the pharmaceutical industry.  
However, oral absorption models continue to evolve and additional uses of these models 
other than just the estimation of rate and extent of absorption can significantly benefit the 
drug development process and improve the therapeutic outcomes of patients.  
 In addition to estimating the rate and extent of oral absorption, the variability 
associated with these estimates is important to determine when decisions about 
developing a dosage regimen need to be made, especially for drugs with narrow 
therapeutic indexes.  Dynamic oral absorption models that can incorporate sources of 
variability and quantify their effects therefore may be of great value in delineating 
variability in plasma concentration-time profiles attributable to oral drug absorption 
processes.  They may also help elucidate how drug physicochemical factors or drug 
formulation factors can be altered to maintain safe and effective plasma drug 
concentrations within a reasonable amount of confidence.   
 A source of variability that can affect the rate and extent of oral absorption during 
the fasted state is the migrating motor complex (MMC).  The MMC is a rhythmically 
recurring cycle of contractile activity that occurs in the stomach and small intestine (Code 
and Marlett 1975).  It consists of three phases of contractile activity.  Phase I is a 
quiescent phase.  Phase II has irregular and infrequent contractions.  Phase III has a burst 
of regular frequent contractions and is commonly referred to as the "housekeeper wave" 
because of its ability to propel remaining stomach and intestinal contents aborally.  The 
housekeeper function of the MMC affects the gastric emptying rate and small intestinal 
transit time of drugs (Bueno, Fioramonti et al. 1975; Oberle, Chen et al. 1990).  
Variability in oral absorption due to the MMC can occur due to drug being taken at 
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different phases of the MMC and different MMC cycle lengths between individuals.  A 
new type of dynamic absorption model was developed based on mass balance and 
stochastic modeling concepts that incorporate the effects of the migrating motor complex 
to estimate the rate, extent, and variability of oral drug absorption during the fasted state.  
The purpose of this report is to describe the development of the program. 
   
Theoretical 
 In the Pulsatile Emptying Transit (PET) model, the GI tract is described by the 
stomach, duodenum, jejunum, and ileum.   Absorption rates obtained from the PET 
model are inputted into a two compartment pharmacokinetic model to obtain a plasma 
concentration time profile.  The first compartment represents the central compartment 
while the second compartment represents a peripheral compartment.  Figure 2-6 shows a 
schematic of the model.   
 Initially the dose of drug and 250 mL of water is delivered to the stomach.  Drug 
empties from the stomach in a pulsatile manner.  The intestinal transit of the pulses is 
directly related to the contractile activity.  Drug pulses are propelled forward only during 
Late Phase II/Phase III of the MMC.  Thus the transit time of the pulses is related to the 
dosing time relative to the time until the end of the next Phase III (TTPIII) and to the time 
it takes for Phase III to migrate to the distal ileum. 
 The following assumptions are made: 
1. No absorption takes place in the stomach 
2. No absorption takes place in the colon 
3. The volume of each pulse is constant 
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4. Phase III activity is always present somewhere in the stomach or small intestine 
5. The drug in each pulse is well mixed 
 TTPIII is a parameter that can have a value between zero and the MMC cycle 
time.  The MMC cycle length used was 150 minutes. 
 
Physiological: 
 In the model, the migrating motor complex consists of three phases (Phase I, 
Phase II, and Phase III).  The lengths of Phase I, Phase II, and Phase III in the stomach 
used in the model were 117 minutes, 18 minutes, and 15 minutes, respectively.  
 To describe the motility of the MMC in the small intestine, available literature on 
the propagation velocity of Phase III was found. 
 
Pulsatile Gastric Emptying: 
 Gastric emptying is predominantly a pulsatile process (Malbert, Mathis et al. 
1994; Anvari, Dent et al. 1995).  In the model, pulses of liquid, containing solid and 
dissolved drug, empty from the stomach into the duodenum every 30 seconds.  A total of 
75 pulses empty into the small intestine.  The first pulse empties from the stomach into 
the intestine after an initial time lag and the last pulse empties into the intestine 37 
minutes later.  Each pulse is assumed to be well-mixed and the pulses do not mix with 
other pulses inside the intestine.   
 The gastric emptying of liquids is assumed to be a first order process.  The 


















where Mo = dose and Vo = volume of water taken with the dose, ke = gastric emptying 
rate, t = time, i = time interval between pulses 
 The value of the first order gastric emptying rate constant for 200 mL of water 
was reported in the literature and depends on the phase of the migrating motor complex 
in the stomach (Oberle, Chen et al. 1990).  During phase I, the lag time = 7 minutes and 
in early phase II, the lag time = 4 minutes.  The gastric emptying rate, ke = 0.11 min
-1 for 
both phase I and II.  The gastric half emptying time (GE1/2) for phase I and phase 2 is 
13.3 min and 10.3 min, respectively.  During late phase II and phase III, the lag time = 2 
minutes and ke = 0.236 min
-1 (GE1/2 = 5 min). 
 
Intestinal Residence Time:     
 In the model, the intestinal residence time of each pulse is dependant on the phase 
of the migrating motor complex in the duodenum at the time of gastric emptying.  For 
example, a pulse that empties into the duodenum during phase I, spends time in the 
duodenum until the next Phase III pushes it into the jejunum and thus it has a longer 
intestinal residence time than a pulse that empties into the small intestine during phase 
III, which is immediately propelled to the jejunum once it enters the duodenum.   
 
Dissolution profile: 
 The Weibull equation is often used to describe in vitro dissolution profiles.  A 
modified version of the Weibull equation was used in the model.  According to the 
Weibull equation, the amount of drug dissolved approaches the original amount of solid 
drug at an infinite time.  However, the model assumes that drug can not continue to 
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dissolve once the solution is saturated.  To take this into account, the Weibull equation 
was modified so that the dissolution rate decreases when the concentration approaches 
the solubility of the drug.  The modified Weibull equation is given by: 























where b = shape factor, A = time scale factor, tlag = lag time, Cs = the drug solubility, 
and Cl = the drug concentration in the intestinal lumen. 
An advantage of using the Weibull equation is that different dissolution profile shapes 
can be simulated by adjusting the shape factor, time scale factor, and lag time.  The effect 
of adjusting these parameters on the dissolution profile shape is shown in Figure 2-1, 
Figure 2-2, and Figure 2-3. 
 
Dissolution rate: 
 Taking the derivative of the modified Weibull equation with respect to time gives 
the dissolution rate. 















ratendissolutio   (2.17) 
Absorption rate: 
 The absorption rate is determined by the product of the flux of the drug (jw) and 
the absorption surface area (A). 
pLLw πRLCPeff2ACPeffAj ⋅⋅⋅=⋅⋅==rateabsorption   (2.18) 
Mass balance for each pulse: 
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Fraction Dose Absorbed: 
 The fraction dose absorbed is obtained by summing the amount of drug absorbed 













Method of Solution 
 The differential equations describing the model were solved numerically using a 
Runge-Kutta-Fehlberg routine that was programmed into Visual Basic in Excel. 
 
Model Parameter Values 
 The values of the parameters inputted into the PET model and 2-compartment PK 
are listed in Appendix A. 
 
Results and Discussion 
 A simulated amount of drug in solution-time profile at different regions of the 
gastrointestinal tract is presented in Figure 2-7a.  The dose was given 80 minutes prior to 
the end of phase III (TTPIII) in the stomach.  Pulses of drug empty into the duodenum 
from the stomach and the drug remaining in the stomach dissolves.  The model assumes 
that no absorption takes place in the stomach.  The amount of drug in solution in the 
stomach is a result of drug dissolving in the stomach and drug gastric emptying.  Initially 
the amount of drug in solution increases in the stomach due to drug dissolution occurring 
in the stomach and little gastric emptying.  The amount of drug in solution decreases in 
the stomach as more of the drug in solution is emptied into the duodenum.  In the 
duodenum, both solid drug and drug in solution empty in pulses from the stomach, solid 
drug dissolves, and drug in solution is absorbed.  The increase in amount of drug in 
solution in the duodenum is a result of dissolution in the duodenum and gastric emptying.  
When the amount of drug absorbed from the duodenum exceeds the sum of the amount of 
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drug dissolving and drug in solution emptying from the stomach, the amount of drug in 
solution in the duodenum decreases.  When phase III of the MMC reaches the duodenum, 
all of the drug in the duodenum is propelled to the jejunum.  In the jejunum, when the 
amount of drug absorbed exceeds the amount of drug dissolving, the amount of drug in 
solution decreases.  When phase III of the MMC reaches the jejunum, all drug in the 
jejunum is propelled to the ileum.  In the ileum, when the amount of drug absorbed 
exceeds the amount of drug dissolving, the amount of drug in solution decreases. 
 Figure 2-7b shows that dosing 18 minutes prior to the end of phase III leads to a 
different amount of drug in solution-time profile than Figure 2-7a.  During phase III, the 
gastric emptying rate of 200 mL of water is approximately twice the emptying rate during 
phase I and phase II.  Therefore, not as much drug can dissolve in the stomach when 
dosed near or during phase III.  In addition, when drug is emptied from the stomach 
during phase III, the drug spends very little time in the duodenum because after a pulse of 
drug empties from the stomach, phase III contractions in the duodenum immediately 
propel the pulse to the jejunum. 
 Figure 2-8 shows a plot of dissolution rate (t85) vs. TTPIII vs. Cmax for a drug 
with a high solubility (33 mg/mL) and high permeability (0.1 cm/min).  The drug is 
classified as Class I under the Biopharmaceutics Classification System (BCS).  The plot 
shows that for drugs with high dissolution rates (85% of the dose dissolves within 15 
minutes) a significantly higher Cmax (> 10%) is obtained if drug is dosed near or during 
phase III. 
 Figure 2-9 shows a plot of effective permeability (Peff) vs. TTPIII vs. Cmax for a 
drug in solution.  The plot shows that dosing this drug near or during phase III results in a 
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significantly higher Cmax when the effective permeability of the drug is higher than 0.04 
cm/minute, approximately the effective permeability of naproxen in the human jejunum. 
 Together, Figures 2-8 and 2-9 suggest that the rates of absorption of BCS Class I 
compounds are not all rate limited by gastric emptying.  Metoprolol is often used as a 
reference compound in the determination of whether a drug has high permeability or not.  
The effective permeability of metoprolol is 0.008 cm/min.  In terms of dissolution, a drug 
that dissolves 85% within 15 minutes is considered to be a drug with a high dissolution 
rate.  The majority of Class I drugs have effective permeabilities higher than metoprolol, 
but lower than naproxen and have a high dissolution rate.  Simulations with the PET 
model suggest that absorption of these Class I drugs would not be rate limited by gastric 
emptying and Cmax would not be greatly affected by dosing these drugs near orduring 
phase III.     
 
Summary 
 The emptying of contents from the stomach in the fasted state is predominantly a 
pulsatile process that is influenced by the phase of the MMC.  The MMC also affects the 
residence time of contents in the small intestine.  An oral absorption model, the PET 
model, was developed to take into account these MMC effects.  The PET model was 
coupled to a compartmental pharmacokinetic model to estimate plasma concentration-
time profiles.  Simulations with the PET model suggest that the maximum plasma 
concentration (Cmax) of drugs with effective permeabilities less than 0.04 cm/min would 
not be significantly affected (< 10%) by the phase of the MMC in which the drug was 
dosed.  Also, for drugs with dissolution rates where less than 85% of the dose dissolves 
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within 15 minutes, Cmax is not significantly affected by the phase of the MMC in which 
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Figure 2-4  3-D plot of fraction of dose absorbed vs. dose number (Do) vs. dissolution number (Dn). 
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Figure 2-7  Amount of drug in solution at different regions of the gastrointestinal tract vs. time (a) 
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A Pharmacokinetic Model Incorporating Gastrointestinal Motility Variation Coupled 
with Discontinuous Gastrointestinal Absorption to Examine the Appearance and 
Absence of Double Peaks in Oral Ranitidine Plasma Concentration-Time Profiles 
 
Introduction 
 The appearance of double peaks in ranitidine plasma concentration-time profiles 
has been widely reported (Garg, Weidler et al. 1983; Shim and Hong 1989; Williams, 
Dukes et al. 1992; Yin, Tomlinson et al. 2003).  Other drugs that have also shown double 
peaks in plasma concentration-time profiles include furosemide (Hammarlund, Paalzow 
et al. 1984), cimetidine (Takamatsu, Welage et al. 2002), celiprolol (Lipka, Lee et al. 
1995), and penicillamine (Bergstrom, Kay et al. 1981).  Several hypotheses have been 
proposed for the occurrence of double peaks in plasma concentration-time profiles 
including: enterohepatic recirculation (Miller 1984), discontinuous absorption 
(Plusquellec, Campistron et al. 1987), and variable gastric emptying and intestinal transit 
rates (Oberle and Amidon 1987). 
 Enterohepatic recirculation is an unlikely explanation for the appearance of 
double peaks in ranitidine plasma concentration-time profiles.  After intravenous 
administration of 50 mg ranitidine in patients, it was found that only 0.7 to 2.6% of the 
dose was recovered in bile after 24 hours.  Similarly, after 300 mg/day of ranitidine was 
administered orally to patients, only 0.1 to 1% of the daily dose was excreted in the bile
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 (Klotz and Walker 1990).  The low amounts of ranitidine recovered in the bile after both 
intravenous and oral dosing suggest that significant ranitidine enterohepatic recirculation 
does not occur and other explanations for the double peak phenomena need to be 
considered. 
 Another explanation for the appearance of double peaks in ranitidine plasma 
concentration-time profiles is discontinuous absorption sites, where a non-absorbing 
gastrointestinal segment lies between two sites of absorption (Plusquellec, Campistron et 
al. 1987).  Evidence for discontinuous absorption sites for ranitidine in the small intestine 
of humans has been reported.  Ranitidine is well absorbed at the proximal (duodeno-
jejunal junction) and distal (ileum) parts of the small intestine.  However it is poorly 
absorbed in the middle part of the small intestine (mid jejunum) (Gramatte, Eldesoky et 
al. 1994).  Simulations with a pharmacokinetic model that incorporated discontinuous 
absorption sites support the discontinuous absorption site hypothesis.  The model was 
able to simulate double peaks similar to those actually observed in ranitidine 
concentration-time profiles (Suttle, Pollack et al. 1992).  Although a discontinuous 
absorption site seems to be a plausible explanation for the appearance of double peaks in 
ranitidine plasma concentration-time profiles, the explanation does not account for the 
absence of double peaks that has been observed in ranitidine plasma concentration-time 
profiles (Williams, Dukes et al. 1992; Yin, Tomlinson et al. 2003).   
 An alternative explanation for double peaks in plasma concentration-time profiles 
is variable gastric emptying rates and intestinal transit due to the migrating motor 
complex.   The migrating motor complex (MMC) is a rhythmically recurring cycle of 
contractile activity that occurs in the stomach and small intestine (Code and Marlett 
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1975).  It consists of three phases of contractile activity.  Phase I is a quiescent phase.  
Phase II has irregular and infrequent contractions.  Phase III has a burst of regular 
frequent contractions and is commonly referred to as the "housekeeper wave" because of 
its ability to propel remaining stomach and intestinal contents aborally.  The housekeeper 
function of the MMC affects the gastric emptying rate and small intestinal transit time of 
drugs (Bueno, Fioramonti et al. 1975; Oberle, Chen et al. 1990).   Using a 
pharmacokinetic model that incorporated variability in gastrointestinal transit, it was 
concluded that the dosing time relative to stomach phasic activity and variable gastric 
emptying are important factors in the occurrence of double peaks in cimetidine plasma 
concentration-time profiles (Oberle and Amidon 1987). 
 Since both discontinuous absorption sites for ranitidine and variability in 
gastrointestinal motility due to the migrating motor complex have been shown to occur in 
humans, it is conceivable that these two explanations for the appearance and absence of 
double peaks observed in ranitidine plasma concentration-time profiles do not have to be 
independent of the other.  The present study was undertaken to develop a 
pharmacokinetic model that takes into account both discontinuous absorption sites and 
variability in gastrointestinal motility due to the motor migrating complex.  Simulations 
with this model may provide new insights into double peak phenomena observed in 
ranitidine plasma concentration-time profiles. 
 
Theoretical 
 In the Pulsatile Emptying Transit (PET) model, the GI tract is described by the 
stomach and small intestine, which is divided into duodenum, jejunum, and ileum.  The 
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stomach is considered to be a reservoir for ingested drug and liquid.  In the stomach, drug 
dissolution occurs, but minimal drug absorption takes place.  The contents in the stomach 
are assumed to be well-mixed. 
 
Physiological: 
 The migrating motor complex (MMC) is a rhythmically contractile cycle that 
takes place in the stomach and small intestine.  A major purpose of the MMC is to clear 
any undigested contents from the GI tract.  There are three phases of the MMC.  Phase I 
is a quiescent phase, with no contractile activity.  Phase II has infrequent contractile 
activity and Phase III has repeated contractile activity and is known as the housekeeper 
wave.  The MMC plays a role in gastric emptying and flow of intestinal contents. 
 A MMC cyclelength of 150 minutes was used.  The lengths of Phase I, Phase II, 
and Phase III in the stomach used in the model were 117 minutes, 18 minutes, and 15 
minutes, respectively.   
 
Pulsatile Gastric Emptying: 
 Pulses of liquid, containing solid and dissolved drug, empty from the stomach into 
the small intestine every 30 seconds.  A total of 75 pulses empty into the small intestine.  
The first pulse empties from the stomach into the intestine after a lag time dependant on 
the MMC at the time of dosing and the last pulse empties into the intestine 37 minutes 
later.  Each pulse is well-mixed and the pulses do not mix with other pulses within the 
intestine.   
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 The gastric emptying of liquids observes a first order process.  The amount of 

















where Mo = dose, ke = first order gastric emptying rate, t = time, and Vo = volume taken 
with dose 
The value of the first order gastric emptying rate constant depends on the phase of the 
migrating motor complex in the stomach.  During phase I, lag time = 7 minutes and in 
early phase II, lag time = 4 minutes.  The gastric emptying rate was ke = 0.11 min
-1 for 
both of these phases (GE1/2 = 13.3 min and GE1/2 = 10.3 min, respectively).  During late 
phase II and phase III, lag time = 2 minutes and ke = 0.236 min
-1 (GE1/2 = 5 min). 
 
Intestinal Residence Time:     
 Once a pulse empties into the small intestine, the drug in the pulse has a finite 
amount of time to be absorbed, the pulse intestinal residence time.  In the model, the 
intestinal residence time of each pulse is dependant on the phase III of the migrating 
motor complex in the intestine at the time of gastric emptying.  For example, a pulse that 
empties into the small intestine during phase I spends more time in the duodenum and 
thus has a longer intestinal residence time than a pulse that empties into the small 
intestine during phase III, which is quickly propelled to the jejunum and spends little time 




 The Weibull equation is often used to describe in vitro dissolution data.  A 
modified version of the Weibull equation was used to model the dissolution profile of 
drug.  According to the Weibull equation, the amount of drug dissolved approaches the 
original amount of solid drug at an infinite time.  However, drug can not continue to 
dissolve once the solution is saturated.  To take this into account, the Weibull equation 
was modified so that the dissolution rate decreases when the concentration approaches 
the solubility of the drug.  The modified Weibull equation is given by: 




















     (3.3) 
where Mpulse = Amount of drug in pulse, tlag = lag time, A = time scale factor, and b = 
shape factor, Cs = drug solubility, and Cl = drug concentration in the intestinal lumen 
An advantage of using the Weibull equation is that different dissolution rates can be 
explored by changing these parameters. 
 
Dissolution Rate: 
 Taking the derivative of the modified Weibull equation with respect to time gives 
the dissolution rate. 















ratendissolutio      (3.4) 
Absorption Rate: 
 The absorption rate is determined by the product of the flux of the drug (jw) and 

























Pulse mass balance: 
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Differential Equations were solved numerically using the Runge-Kutta-Fehlberg method 
which was programmed into Visual Basic in Excel. 
 
Methods 
 The absorption rate obtained from the PET model was inputted into a 2 
compartment pharmacokinetic model.  All parameters inputted into the model were 
obtained from the literature except for the human duodenal and ileal effective 
permeabilities of ranitidine which have not been reported.  All simulations were based on 
a single dose of drug with time = 0 representing the time of dosing.  Pharmacokinetic 
parameters were varied in each simulation to assess their influence on the concentration-
time profile.  The effects of phase of dosing and gastric emptying rate were investigated 
by varying the parameter time to the end of the next phase III (TTPIII).  Different 
permeability values can be inputted in the PET model for the duodenum, jejunum, and 
ileum.  The inputs to the model simulations are listed in Appendix B. 
  
Results 
 The simulated plasma concentration-time profiles produced when dosing at 
different times with respect to phase III are presented in Figure 3-2.   In simulations 
where only the time to the end of the next phase III (TTPIII) decreased, the plasma 
concentration of the first peak (Cmax1) and time of the first peak (Tp1) decreased, the 
plasma concentration of the second peak (Cmax2) increased and time of the second peak 
(Tp2) was unchanged.  When TTPIII was between 0 and 20 minutes, Cmax1 disappeared 
and only one peak was observed. 
 58 
 The effects of changes in dissolution rate on the simulated plasma concentration-
time profiles are shown in Figure 3-3.  Increasing dissolution rate, resulted in increased 
Cmax1 and Cmax2 decreased Tp2 and unchanged Tp1. 
 The effects of changes in the effective permeability of the duodenum and ileum 
on the simulated plasma concentration-time profiles are displayed in Figure 3-4 and 
Figure 3-5, respectively.  Increased effective permeability in the duodenum increased 
Cmax1 and Cmax2 and decreased Tp1 and Tp2.  At increasingly high effective permeabilities 
in the duodenum, the second peak becomes less pronounced.  Increased effective 
permeability in the ileum has no effect on Cmax1 and Tp1, but increases Cmax2 and 
decreases Tp2. 
 The effects of the intravenous pharmacokinetic parameters on simulated plasma 
concentration-time profiles are displayed in Figures 3-6, 3-7, 3-8, and 3-9.  Increasing k12 
decreases Cmax1 and Cmax2, has no effect on Tp1, and increases Tp2.  Increasing k21, 
increases Cmax1 and Cmax2, has no effect on Tp1, and increases Tp2.  Increasing kout, 
decreases Cmax1 and Cmax2, has no effect on Tp1, and decreases Tp2.  Increasing Vc, 
decreases Cmax1 and Cmax2 and has no effect on Tp1 and Tp2. 
 
Discussion 
 Factors that affect oral absorption (drug dissolution, variable gastric emptying, 
variable effective permeabilities along the intestine, and intestinal transit times) were 
taken into account in the present model.  The model is described by the stomach, 
duodenum, jejunum and ileum.  The transit of gastrointestinal contents was modeled to 
be dependent on the migrating motor complex.  
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 Twelve plots showing a diversity of shapes for orally administered ranitidine 
plasma concentration-time profiles are shown in Figure 3-1.  Each plot has two plasma 
concentration-time profiles taken from a single individual one week apart.  The dotted 
plots were taken one week after the solid plots.  The majority of the plasma 
concentration-time profiles show double peaks.  Among the plasma concentration-time 
profiles that have double peaks, differences in the heights and timing of appearance for 
the first and second peaks are very apparent.  Even within the same individual, the 
heights and time of appearance for the first and second peaks differ slightly when 
ranitidine is given one week later.    
 Simulations with the PET model show that the heights of the two peaks in 
ranitidine plasma concentration-time profiles can be affected by several parameters 
including TTPIII, drug dissolution rate, effective permeability values, and intravenous 
PK parameters.  All of these parameters may differ between individuals.  The wide 
variability in the shapes of the concentration-time profiles between individuals is striking 
and suggests that the shape of each of the profiles is a result of the combination of these 
parameters in the individual and each individual has different combinations of these 
parameters.    
 However within individuals, effective permeability patterns along the intestine 
and intravenous PK parameters are not expected to vary significantly.  Thus, the 
absorption pattern of ranitidine along the small intestine is a characteristic of an 
individual.  Given similar flow patterns in the small intestine, one would expect to see 
similarly shaped concentration-time profiles within the same individual.  The data 
showing pairs of concentration-time profiles obtained one week apart from 12 individuals 
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show this to be the true except for one pair of concentration-time profiles.  Simulations 
with the PET model show that dosing at different phases of the MMC, produce slight 
changes in the peak heights and time shifts in plasma concentration time profiles, but the 
overall shape of the profiles are extremely similar the majority of the time.  In 
simulations, exceptions occurred when drug was given during phase III of the motor 
migrating complex which produced plasma concentration-time profiles with single peaks.  
When drug is dosed during phase III, little drug is absorbed in the duodenum because 
drug is rapidly propelled to the jejunum by phase III contractions in the duodenum.  
Assuming that the MMC phase that the dose of ranitidine is given is random, the 
occurrence of single peaks rather than double peaks in ranitidine plasma concentration 
curves is expected to occur infrequently, approximately 15% of the time. 
 
Summary 
 Simulations with the PET model with a discontinuous PK model support 
discontinuous absorption sites as an explanation for the appearance of double peaks in 
ranitidine plasma concentration-time profiles.  Simulations also suggest that single peaks 
may occur when drug is dosed during phase III of the migrating motor complex.  When 
drug is dosed during phase III, absorption in the duodenum, a high absorption site, may 
be bypassed resulting in a single peak.  Since phase III makes up roughly 15% of the 
MMC cycle, single peak plasma concentration-time profiles are expected to appear 
infrequently.  Simulations with the PET model show that similarly shaped concentration-
time profiles can be expected for the same individual the majority of the time.  For an 
individual, simulations show that the height and timing of peaks in plasma concentration-
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time profiles can differ depending on the phase of dosing; however, the general shape of 
the double peaks is similar.  Exceptions occurred when simulations produced single peak 
plasma concentration curves when ranitidine was dosed during phase III of the MMC.   
Simulations show that slight differences in peak heights and timing of peaks may also be 
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b = 1.6, A = 100, tlag = 0
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Applying Solubility Product and Solution Complexation Relationships to 
Preliminary Cocrystal Dissolution Studies 
 
Introduction 
 Dissolution is a process that affects the rate and extent of absorption of orally 
administered pharmaceutical solids from the gastrointestial tract and therefore is a key 
process for drug absorption and drug effectiveness.  Before a d ug can be absorbed from 
the gastrointestinal tract, it needs to be dissolved in the gastrointestinal fluid.  The drug 
dissolution rate can be the rate limiting step in absorption and can prevent sufficient 
amounts of drug from being absorbed by the gastrointestinal tract to elicit the desired 
therapeutic effect.  Altering solid state properties of compounds through the formation of 
salts, solvates, polymorphs or amorphous solids is a strategy commonly used to try to 
obtain more favorable compound dissolution rates (Huang and To g 2004; Rodriguez-
Spong, Price et al. 2004).  The formation of solid state complexes or cocrystals offers an 
additional option to alter solid state properties of compounds without changing covalent 
bonds.  The formation of cocrystals may be particularly helpful for compounds that are 
non-ionizable and when the other commonly used methods for altering solid state 
properties do not produce the desired results (Stahly 2007).  Although the utility of 
forming cocrystals to alter dissolution rates has been demonstrated for several
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 compounds  it is not well understood how dissolution rate may be affected by cocrystal 
component selection.  
 A mechanistic understanding of cocrystal dissolution may aid in the rational 
selection of components for the formation of cocrystals to achieve a desired dissolution 
rate for a compound.  The dissolution rate of pharmaceutical solids is commonly 






s −=      (4.1) 
where, dm/dt is the dissolution rate, m is the mass of olute dissolved at time t, D is the 
diffusion coefficient, S is the surface area of the dissolving solid, C is the concentration 
of the dissolved solute in the bulk solution at time t, and Cs is the solubility of the solute 
in a thin unstirred layer of solvent with a thickness h.  T e driving force for dissolution is 
the concentration gradient across the unstirred layer of solvent.  According to the 
Brunner-Nernst equation, increasing the solubility of the pharmaceutical solid increases 
the concentration gradient across the unstirred layer of solvent and thus can increase the 
dissolution rate of the compound.   
 Understanding the solubility behavior of cocrystals in olutions of cocrystal 
components may increase our knowledge of how selecting different cocrystal 
components would affect the dissolution rate of cocrystals.  Theoretical analysis and 
experimental results presented elsewhere (Nehm, Rodriguez-Spong et al. 2006) show that 
the solubility of cocrystal is dependent on the concentration of cocrystal components in 
solution and the cocrystal solubility product and the binding constants of complexes 
formed in solution can explain this dependence.  The purpose of the studies presented in 
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this manuscript is to use solubility product and solution complexation concepts to 
investigate how cocrystal components may affect cocrystal dissolution. 
 
Theoretical 
 In search of caffeine cocrystals that would dissolve less rapidly in aqueous 
solutions than caffeine itself, an equation to estimate the relative dissolution rates of a 
cocrystal and the active pharmaceutical ingredient (API) was derived using mass 
transport film theory concepts (Higuchi and Pitman 1973).  The relative rate of 
dissolution (R) of caffeine:gentisic acid cocrystal and caffeine was found to be well 





R =      (4.2) 
where ATo is the stoichiometric solubility of the cocrystal in the dissolution medium and 
SA is the solubility of the uncomplexed drug in the dissolution medium.  Equation 2 states 
that the relative rates of dissolution can be estimated by the ratio of the stoichiometric 
solubility of the cocrystal and solubility of the API.  The validity of the equation depends 
on whether the stoichiometric solubility of the cocrystal in the dissolution media is 
representative of the solubility of the cocrystal at the solid/liquid interface of the 
diffusion layer.  Salts can increase their own dissolution rate by acting as their own 
buffers to change the pH in the diffusion layer, thus increasing the solubility of the parent 
compound in the unstirred diffusion layer (Berge, Bighley et al. 1977).  Cocrystals may 
similarly increase their own dissolution rates by mechanisms that can increase cocrystal 
solubility within the unstirred diffusion layer.  To investigate this mechanism, solubility 
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product and solution complexation relationships were used to construct phase solubility 
diagrams.  
 Mathematical models that explain the shape of phase solubility diagrams for 1:1 
carbamazepine:nicotinamide cocrystal (CBZ:NCT) in ethanol, 2-propanol and ethyl 
acetate have been derived using solubility product and solution complexation 
relationships and are presented elsewhere (Nehm, Rodriguez-Spong et al. 2006).  When 
dissolution of 1:1 cocrystal of an API (A) and ligand (B)leads to the formation of soluble 
complexes, the equilibrium reactions are given by: 
ABsolid Asoln + Bsoln
Ksp
      (4.3)     
ABsoln
K1:1
Asoln + Bsoln      (4.4) 
When the activity coefficients are unity, the equilibrium constants for these reactions can 
be described by the solubility product 
[ ][ ]BAK sp =        (4.5) 




K 1:1 =      (4.6) 
where [A], [B] and [AB] are the molar concentrations at equilibrium of the A cocrystal 
component, B cocrystal component, and soluble AB complex, respectively. 
Mass balances for A and B in solution give 
[ ] [ ] [ ]ABAA T +=      (4.7) 
[ ] [ ] [ ]ABBB T +=      (4.8) 
A or B can exist in solution either as free species or as a 1:1 soluble complex.  
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Substituting equation 7 into equation 8 gives 
[ ] sp1:1 KKAB =      (4.9) 
The 1:1 soluble complex concentration is a constant and is determined by taking the 
product of the solubility product and 1:1 complexation constant.   
Substituting equation 11 into equations 9 and 10 gives  
[ ] [ ] sp1:1T KKAA +=      (4.10) 
[ ] [ ] sp1:1T KKBB +=      (4.11) 
When CBZ:NCT cocrystal is dissolved in pure solvent, the resulting measured cocrystal 
solubility is the stoichiometric cocrystal solubility, where: 
[ ] [ ] spKBA ==      (4.12) 
At the stoichiometric solubility for a 1:1 cocrystal AB, the free concentrations of A and B 
are equal and the total A and B concentrations are given by: 
[ ] sp1:1spTo KKKA +=      (4.13) 
[ ] sp1:1spTo KKKB +=      (4.14) 
At nonstoichiometric conditions for a 1:1 cocrystal AB, the free concentrations of A and 
B are not equal.  The free concentrations of A and B have an inverse relationship given 
by the solubility product.  Increasing the ligand con entration, [B], decreases [A] and 
thus decreases cocrystal solubility.  Decreasing the ligand concentration, [B], increases 
[A] and thus can increase the cocrystal solubility.  Substituting equation 7 into equation 
12 gives: 




A +=      (4.15) 
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Substituting equation 13 into equation 14 gives: 






=      (4.16)    
 The maximum value for the free concentration of A, [A] is given by the intrinsic 
solubility of A, [A]o, in the dissolution medium.  The maximum value of [A]T is given 
by: 






=      (4.17) 
where 




KK[B]B +=+=      (4.18) 
 The minimum value for [A] occurs when the free B cone tration is equal to the 
intrinsic solubility of B, [B]o.  The minimum value for [A]T is given by:  












=      (4.19) 
where 
[ ] [ ] sp1:1oT KKBB +=      (4.20) 
If nonstoichiometric conditions exist in the unstirred layer, the relative dissolution rate 
between cocrystal and API may deviate from equation 2 and usi g nonstoichiometric 
cocrystal solubility values may give better estimates of the relative dissolution rate.  
Nonstoichiometric conditions may occur in the unstirred layer if the cocrystal 
components, A and B, diffuse through the unstirred layer at different rates resulting in 





 Anhydrous monoclinic carbamazepine (CBZ(III); lot #093K1544 USP Grade and 
99.8% pure) and nicotinamide (NCT(I); lot #093K0018) were purchased from Sigma 
Chemical Company (St. Louis, MO) and used as received.  Ethylacetate and 2-propanol 
were of HPLC grade and were purchased from Fisher Scientific (Fair Lawn, NJ).  
Anhydrous ethanol (200 proof) was of USP grade and was purchased from Pharmco 
(Brookfield, CT).  All solvents were used as received. 
 
Preparation of Carbamazepine:Nicotinamide (CBZ:NCT): 
 CBZ:NCT cocrystals (1:1 molar ratio) were prepared by dissolving NCT(I) (0.35 
g; 2.83 mmol) in ethyl acetate (50 g) and adding CBZ(III) (0.67 g; 2.83 mmol) at 40 ± 5 
°C with constant stirring.  The solution was quickly cooled to 25 °C in an ice water bath 
and allowed to crystallize over 2 h.  Crystals of CBZ:NCT were harvested by vacuum 
filtration and dried at room temperature (22-23 °C) under reduced pressure (25 mmHg) 
on Whatman #50 filter paper (Maidstone, England) for 30 minutes to remove loosely 
bound solvent.  The cocrystal form was confirmed by x-ray powder diffraction.  
CBZ:NCT was stored at 5 °C over anhydrous calcium sulfate. 
 
X-ray Powder Diffraction (XRPD): 
 XRPD analyses were carried out on a Rigaku Miniflex X-ray diffractometer 
(Tokyo, Japan) using Cu Kα radiation (λ = 1.54 Å), tube voltage of 30 kV, and tube 
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current of 15 mA.  The intensities were measured at 2-theta values from 2.5° to 40° at a 
continuous scan rate of 2.5°/min. 
 
Compact Formation: 
 Either 80 mg of CBZ(III) or CBZ:NCT powder was placed in a rotating disk die 
and compressed with a hydraulic press (Fred Carver, Inc., Summit, NJ) to form a 1.2 cm 
diameter compact.  All compacts were inspected for cracks on the surface.  If any 
imperfections were seen, the compact was not used in the experiments.  Sometimes an 
entire compact would detach from the rotating disk die upon almost immediately after 
being submerged in the solvent.  If this occurred, compact compression conditions were 
changed to prevent this from occurring.  Studies looking at compact compression 
conditions and dissolution rate have found that different compact compression conditions 
for CBZ:NCT did not significantly affect the dissolution rate (Spong 2005).  Table 4-1 
shows the compression conditions used for CBZ and CBZ:NCT in each solvent. 
 
Dissolution Experiments: 
 Intrinsic dissolution rates of CBZ(III) and CBZ:NCT in ethanol, 2-propanol and 
ethyl acetate were determined with rotating disk experiments.  Experiments were 
conducted in a jacketed beaker containing 250 mL of solvent.  The solvent was 
maintained at 25 °C with a circulating temperature bath running through the jacketed 
beaker.  The rotating disk was attached to an overhead synchronous motor (Cole-Parmer 
Scientific, Niles, IL) and rotated at 100 rpm.  A Servodyne Mixer Controller (Cole-
Parmer Scientific, Niles, IL) was used to control and monitor the rotation speed of the 
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disk.  A lid for the jacketed beaker and parafilm were used to prevent evaporation of 
solvent.  Samples of 0.5 mL were taken from the dissolution medium at three minute 
intervals for 30 minutes.  The amount of dissolution medium taken out for sampling was 
replaced with the same amount of pure solvent.  Samples tak n from the dissolution 
media were filtered with a 0.22 µm nylon filter and directly analyzed with high 
performance liquid chromotagraphy (HPLC).  All experiments were done in triplicate, 
except for the CBZ:NCT dissolution experiments in ethanol, which were repeated four 
times. 
High Performance Liquid Chromatography (HPLC): 
 The HPLC instrument (Waters, Milford, Massachusetts) was equipped with a UV 
diode array detector (Waters, Milford, Massachusetts) and contained a Xterra™ C18 (5 
µm particle size, 6 x 250 mm) column (Waters, Milford, Massachusetts).  The maximum 
wavelength for absorbance for CBZ was set to 285.1 nm.  The maximum wavelength for 
absorbance for NCT was set to 260.7 nm.  A 12 minute isocratic method was used.  The 
mobile phase consisted of 70/30 water/acetonitrile with 0.1% trifluoroacetic acid and ran 
at a flow rate of 1 mL/min.  The injection volume was 25 µL.  Each sample was injected 
twice and the values obtained from the two injections were averaged.  . 
 
Statistical Analysis 
 A student's t-test was used to test statistically whether a difference between the 
predicted and measured relative rates of dissolution was observed. 
 
Solubility, Ksp and K1:1 Values 
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 Solubilities for CBZ, NCT, and CBZ:NCT in ethanol, 2-propranol, and ethyl 
acetate are reported elsewhere (Nehm, Rodriguez-Spong et al. 2006) and listed in Table 
4-2.  Ksp and K1:1 values for CBZ:NCT for the three organic solvents are also reported 
(Nehm, Rodriguez-Spong et al. 2006) and listed in Table 4-3. 
 
Mathematical Modeling of Phase Solubility Diagrams 
 Mathematical models that consider equilibria and solid state complex have been 
reported elsewhere (Nehm, Rodriguez-Spong et al. 2006).  For the p es nt analysis, mass 
balances were done starting with cocrystal components rather than cocrystal.  The 
equations that describe phase solubility diagrams for 1:1 and 1:2 cocrystals where 
complexes form in solution are given in the appendix. 
 
Results and Discussion 
 Theoretical phase solubility diagrams for CBZ:NCT cocrystal as a function of the 
ligand (NCT) are plotted with reported CBZ:NCT cocrystal olubility values in ethanol, 
2-propanolol, and ethyl acetate solutions in Figures 4-1, 4-2, and 4-3, respectively.  
Solubility studies conducted by Nehm et al. show that addition of the ligand, NCT, in 
excess of the stoichiometric composition reduces the solubility of CBZ:NCT cocrystal in 
three organic solvents.  Since the solubility studies wre conducted with CBZ:NCT 
cocrystal in pure solvent or in NCT solutions, NCT was always either equal to or in 
excess of the stoichiometric composition.  Solubility experiments where NCT was below 
the stoichiometric composition have not been conducted.  In solutions where soluble 
complexes form, theoretical phase solubility diagrams suggest that decreasing NCT 
 83 
below the stoichiometric composition would increase the solubility of CBZ:NCT 
cocrystal.  Therefore decreasing the ligand concentration below the stoichiometric 
composition in the unstirred diffusion layer during dissoluti n is a possible mechanism to 
achieve higher dissolution rates for 1:1 cocrystals thanpredicted by equation 2.  During 
the dissolution of 1:1 cocrystals, nonstoichiometric conditions may occur in the unstirred 
layer due to the difference in diffusion rates between th  free cocrystal components 
through the unstirred layer. The diffusion coefficient for each species in the unstirred 
layer can be estimated using the Stokes-Einstein equation: 
πηr6
Tk
D B=      (4.21) 
where kB = Boltzman constant, T = temperature, η = viscosity of the suspending fluid, 
and r = radius of sphere. 


















=      (4.22) 
where m = mass and ρ = density 


























































     (4.23) 
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The ratio of carbemazepine to nicotinamide diffusion coeffici nts using equation 25 is 
0.80.   
 Theoretical and experimental relative dissolution rates between cocrystal 
CBZ:NCT (1:1) and single component crystal CBZ in three organic solvents are 
presented in Table 4-4.  The theoretical relative dissolution rates were calculated using 
the ratio of stoichiometric CBZ:NCT cocrystal solubility to single CBZ crystal solubility.  
Although differences between the experimental and theoretical relative dissolution rates 
were observed in all three solvents, the differences were found not to be statistically 
significant.  To detect a statistically significant difference in the relative dissolution rates 
a much greater change in dissolution rates than what was observed in the described 
experiments are necessary.   
 
Summary 
 Theoretical phase solubility diagrams for CBZ:NCT cocrystals in organic solvents 
show that cocrystal solubility can either increase or decrease when the ligand, NCT, 
concentration differs from the stoichiometric compositi n.  If non-stoichiometric 
cocrystal solubilities exist in the unstirred boundary layer during dissolution, relative 
dissolution rates determined experimentally would be expected to deviate from equation 
2.  However, results of preliminary experiments described above do not show a 
statistically significant difference between relative dissolution rates determined 
experimentally and equation 2.  The lack of a statistically significant result may be due to 
the small differences in diffusion coefficients betw en carbamazepine and nicotinamide.  
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Dissolution studies with other cocrystals in different solvent systems may demonstrate 
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Figure 4-1  Theoretical phase solubility diagram of CBZ:NCT in ethanol at 25 ºC (---) overlayed on 

























































Figure 4-2 Theoretical phase solubility diagram of CBZ:NCT in 2-propanol at 25 ºC (---) overlayed 
























































Figure 4-3 Theoretical phase solubility diagram of CBZ:NCT in ethyl acetate at 25 ºC (---) overlayed 

































Table 4-1: Compression conditions for compact formation. 
Compact Ethanol Ethyl Acetate 2-propanol 
CBZ (80 mg) 5000 psi for 30 min 5000 psi for 30 min 4500 psi for 30 min 








































Table 4-2 Solubilities of CBZ:NCT, CBZ(III) and NCT in three organic solvents at 25 ºC.  Data from 




































Table 4-3 Ksp and K1:1 for CBZ:NCT in three organic solvents at 25 ºC.  Data from (Nehm, 
























































relative dissolution rates in 



















Ethanol 1.074 ± 0.028a 0.848 ± 0.170a -20% 
Ethyl Acetate 0.545 ± 0.023b 0.473 ± 0.206b -15% 
2-propanol 1.128 ± 0.116c 1.286 ± 0.176c +14% 
a Statistically insignificant difference in ratios, p-value > 0.05.  b Statistically insignificant 
difference in ratios, p-value > 0.05.  c Statistically insignificant difference in ratios, p-
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 An oral absorption model, the Pulsatile Emptying and Transit (PET) model, was 
developed to take into account the effects of variable gastrointestinal motility on oral 
absorption.  When coupled to a compartmental pharmacokinetic model, simulations with 
the PET model suggested that the maximum plasma concentration (Cmax) of drugs with 
effective permeabilities less than 0.04 cm/min would not be significantly affected (less 
than 10%) by the phase of the MMC in which the drug was dosed.  Also, for drugs with 
dissolution rates where less than 85% of the dose dissolves within 15 minutes, Cmax is not 
significantly affected by the phase of the MMC in which the drug was dosed.  Cmax is a 
measure of bioequivalence used to evaluate how quickly the drug is absorbed.  In 
summary, the results of the simulations suggest that the MMC will not significantly affect 
the rate of drug absorption unless the drug has an extremely high effective permeability 
and rapid dissolution rate. 
The PET model was also used to examine the appearance and absence of double 
peaks in oral ranitidine plasma concentration-time profiles.  Simulations with a region 
dependent permeability PET model with compartmental PK support discontinuous 
absorption sites as an explanation for the appearance of double peaks in ranitidine plasma 
concentration-time profiles.  Simulations also suggest that single peaks may occur when 
drug is dosed during phase III of the migrating motor complex.  When drug is dosed 
during phase III, absorption in the duodenum, a high absorption site, may be bypassed
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resulting in a single peak.  Since phase III makes up roughly 15% of the MMC cycle, 
single peak plasma concentration-time profiles are expected to appear infrequently.  
Simulations with the PET model show that similarly shaped concentration-time profiles 
can be expected for the same individual the majority of the time.  For an individual, 
simulations show that the height and timing of peaks in plasma concentration-time 
profiles can differ depending on the phase of dosing; however, the general shape of the 
double peaks is similar.  Exceptions occurred when simulations produced single peak 
plasma concentration curves when ranitidine was dosed during phase III of the MMC. 
In the ranitidine simulations, although the plasma concentration levels are similar 
to those observed in patients, the times of the dip between the double peaks in the 
simulations (1.5 hours after dosing) tended to occur earlier than those observed in 
patients (2-3 hours after dosing).  A possible reason for this inconsistency between the 
simulated and observed plasma concentration-time profiles is that in the model, the 
jejunum permeability was the same way throughout the whole jejunum.  However, the 
decrease in ranitidine permeability in the jejunum occurs after the proximal jejunum.  
Therefore dividing the jejunum into a proximal and distal region in the model may give 
simulations that better coincide with the timing of the dip in the observed plasma 
concentration-time profile. 
 In addition to modeling oral absorption, solubility product and solution 
complexation relationships were used to model preliminary cocrystal dissolution studies 
Theoretical phase solubility diagrams for CBZ:NCT cocrystals in organic solvents 
showed that cocrystal solubility can either increase or decrease when the ligand, NCT, 
concentration differs from the stoichiometric composition.  If non-stoichiometric 
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cocrystal solubilities exist in the unstirred boundary layer during dissolution, relative 
dissolution rates determined experimentally would be expected to deviate from the ratio 
of the stoichiometric CBZ:NCT cocrystal solubility and CBZ(III) solubility .  However, 
results of the preliminary dissolution experiments did not show a statistically significant 
difference between relative dissolution rates determined experimentally and the ratio of 
the stoichiometric CBZ:NCT cocrystal solubility and CBZ(III) solubility.  The lack of a 
statistically significant result may be due to the small differences in diffusion coefficients 
between carbamazepine and nicotinamide.  Dissolution studies with other cocrystals in 
different solvent systems may demonstrate greater increases in the rates of dissolution for 

























































































1:1 cocrystal stoichiometric solubility determination 










Mass balance of A 
 
1=+ ABA  
 
Mass balance of B 
 
1=+ ABB  
 
The moles of B is equal to the moles of A in solution 








At the 1:1 cocrystal stoichiometric solubility, the moles of B is equal to A 
 
1:2 cocrystal stoichiometric solubility determination 










Mole balance of A 
 
12 =++ ABABA  
 
Mole balance of B 
 
22 2 =++ ABABB  
 
The moles of B is twice the moles of A in solution 














At the 1:2 cocrystal solubility, the moles of B is equal to 2A + AB. 
